- Home
- KXIN vs QLGN Comparison
KXIN vs QLGN Comparison
Compare KXIN & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KXIN
- QLGN
- Stock Information
- Founded
- KXIN 2015
- QLGN 1996
- Country
- KXIN China
- QLGN United States
- Employees
- KXIN N/A
- QLGN N/A
- Industry
- KXIN Retail-Auto Dealers and Gas Stations
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- KXIN Consumer Discretionary
- QLGN Health Care
- Exchange
- KXIN Nasdaq
- QLGN Nasdaq
- Market Cap
- KXIN 3.1M
- QLGN 3.4M
- IPO Year
- KXIN N/A
- QLGN N/A
- Fundamental
- Price
- KXIN $1.76
- QLGN $4.09
- Analyst Decision
- KXIN
- QLGN
- Analyst Count
- KXIN 0
- QLGN 0
- Target Price
- KXIN N/A
- QLGN N/A
- AVG Volume (30 Days)
- KXIN 727.4K
- QLGN 51.4K
- Earning Date
- KXIN 11-26-2019
- QLGN 11-14-2024
- Dividend Yield
- KXIN N/A
- QLGN N/A
- EPS Growth
- KXIN N/A
- QLGN N/A
- EPS
- KXIN N/A
- QLGN N/A
- Revenue
- KXIN $12,679,000.00
- QLGN N/A
- Revenue This Year
- KXIN N/A
- QLGN N/A
- Revenue Next Year
- KXIN N/A
- QLGN N/A
- P/E Ratio
- KXIN N/A
- QLGN N/A
- Revenue Growth
- KXIN N/A
- QLGN N/A
- 52 Week Low
- KXIN $1.66
- QLGN $3.34
- 52 Week High
- KXIN $64.80
- QLGN $30.50
- Technical
- Relative Strength Index (RSI)
- KXIN 36.41
- QLGN 41.77
- Support Level
- KXIN $1.66
- QLGN $3.53
- Resistance Level
- KXIN $1.96
- QLGN $4.39
- Average True Range (ATR)
- KXIN 0.15
- QLGN 0.35
- MACD
- KXIN 0.18
- QLGN 0.06
- Stochastic Oscillator
- KXIN 19.63
- QLGN 43.91
About KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company primarily generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.